Maria Pia Sormani, PhD, University of Genoa, Genoa, Italy, comments on the collaboration between the Italian Multiple Sclerosis Society, the Italian Neurological Society, and the Italian Registry on COVID-19 data collection. One of the project’s objectives is to test if patients receiving different disease modifying therapies (DMTs) are able to develop antibodies against SARS-CoV2 using patients’ blood samples. Dr Sormani highlights the strong collaboration and the positive impact of the project. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Dr Maria Pia Sormani received consulting fees from Biogen, Novartis, Roche, Merck, Sanofi, Celgene, Geneuro, Immunic & Medday.